During treatment with SA, patients showed higher mean minimum Hb levels (94.7 ± 29.8 g/L vs. 74.7 ± 19.7 g/L, p < 0.001) and fewer patients showed persistent severe anemia (39% vs. 61%, p = 0.007) than before SA therapy. The gene discussed is GSTM1; the disease is anemia.